31 citations,
March 2018 in “Frontiers in Immunology” The document concludes that anti-dsDNA antibodies are not unique to SLE and their use as indicators is doubtful, highlighting the need for better understanding and classification of the disease.
3 citations,
June 2020 in “Open access rheumatology” A patient with Rhupus was diagnosed with Rowell syndrome and treated with various medications.
1 citations,
February 2023 in “International Journal of Rheumatic Diseases” This case-based review analyzed three instances of tuberculosis (TB) mimicking systemic lupus erythematosus (SLE) flare, with patients aged 27 to 32 years. These cases lacked typical SLE features like butterfly erythema, lupus hair, alopecia, or proteinuria. The study found that TB could induce the production of various autoantibodies, such as anti-nuclear and anti-double-stranded DNA antibodies, which are usually seen in SLE. However, these autoantibodies did not change the clinical or radiographic presentation of TB and were not present after the infection resolved. The resistance of SLE-like symptoms to steroid and immunosuppressive treatments suggested an infectious cause. The findings highlight the importance of considering active TB in patients with SLE-like symptoms, especially when specific serological markers and hypocomplementemia are present.
The study on systemic lupus erythematosus (SLE) in India, involving 40 patients, found that the mean age of onset was 23.3 years with a female to male ratio of 19:1. Common skin lesions included malar rash (77.5%), photosensitivity (70%), and non-scarring alopecia (60%). Systemic manifestations frequently observed were arthritis (77.5%) and nephritis (30%). Among patients with only cutaneous manifestations, a significant number had positive serological markers such as antinuclear antibody (85%) and anti-double-stranded DNA (57%). The findings suggest that early identification of SLE through skin lesions and serological profiles can precede systemic symptoms, highlighting the importance of environmental factors in the Indian context.
2 citations,
January 2012 in “PubMed” Mycophenolate mofetil is effective for treating severe lupus nephritis in children.
3 citations,
January 2023 in “The Egyptian Rheumatologist” Macrophage activation syndrome can be a deadly first sign of systemic lupus erythematosus.
1 citations,
January 2021 in “Journal of the American Academy of Dermatology” Careful histologic examination is crucial to differentiate types of bullous lesions in cutaneous lupus erythematosus.
60 citations,
September 2013 in “Alimentary Pharmacology & Therapeutics” Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
35 citations,
August 2001 in “Journal of Cutaneous Medicine and Surgery” Tacrolimus is effective for various skin conditions with fewer side effects than cyclosporine.
4 citations,
July 2001 in “Journal of Cutaneous Medicine and Surgery” Tacrolimus is an effective treatment for several skin conditions with fewer side effects than cyclosporine.
144 citations,
September 2006 in “Clinics in Dermatology” Lupus affects the body and skin, causing joint pain and skin issues that can be treated with steroids and antimalarial drugs.
10 citations,
October 2010 in “Hepatology” Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.
1 citations,
January 2021 in “Arthritis Research & Therapy” About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.
January 2018 in “Przegla̧d dermatologiczny” The Polish Dermatological Society recommends personalized treatment for cutaneous lupus, including lifestyle changes, medications, and monitoring, with specific drugs for severe cases.
213 citations,
October 2017 in “Rheumatology” The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.
February 2024 in “Journal of dermatology” CGF therapy may help hair regrowth and improve scars in DLE patients.
11 citations,
October 2021 in “Orphanet journal of rare diseases” Patients with RASopathies are at risk for autoimmune disorders and should be routinely screened.
2 citations,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
May 2021 in “Medicina internă” High-dose corticosteroid treatment helped improve symptoms in a patient with Adult Onset Still Disease.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
November 2022 in “The Indian journal of chest diseases & allied sciences” Isoniazid can rarely cause hair loss, which is reversible after stopping the drug.
39 citations,
September 2017 in “The Open Rheumatology Journal” Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.
28 citations,
July 2002 in “Australasian Journal of Dermatology” Lupus can look like hair loss from alopecia areata but needs different treatment.
16 citations,
July 2002 in “Australasian Journal of Dermatology” A woman with lupus experienced skin death due to a blood clotting disorder after stopping a blood thinner, which healed with treatment.
15 citations,
July 2002 in “Australasian Journal of Dermatology” Two plywood factory workers developed contact dermatitis from phenol-formaldehyde resin, a known allergen.
14 citations,
November 2006 in “Clinical and Experimental Dermatology” A girl with no hair neglect developed plica neuropathica in the hospital, lost all her hair, but it grew back.
10 citations,
July 2002 in “Australasian Journal of Dermatology” Careful management of blood thinners is crucial for lupus patients with APS.
8 citations,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
3 citations,
September 2021 in “Journal of Nepal Medical Association” A woman with complete hair loss and severe hyperthyroidism was successfully treated with azathioprine and hydroxychloroquine.
3 citations,
March 2017 in “Case Reports in Dermatology” A woman with lupus improved significantly from scalp hair loss after treatment, highlighting the need to identify psoriatic alopecia in lupus patients to avoid permanent hair loss.